Table 4

Pulmonary function and resting breathing pattern measurements# 2 h post-dose at the end of each 2‐week treatment period

PlaceboSalmeterol
FEV1 L1.04±0.08 (40)1.24±0.09 (48)**
FVC L2.24±0.12 (60)2.67±0.13 (72)**
FEV1/FVC %45±2 (64)46±2 (64)
PEFR L·s−13.35±0.21 (63)4.16±0.23 (79)**
FEF50% L·s−10.47±0.06 (12)0.55±0.07 (14)*
FIF50% L·s−12.74±0.243.35±0.28**
TLC L7.29±0.26 (121)7.22±0.27 (120)
FRC L5.52±0.23 (172)5.17±0.26 (160)**
SVC L2.66±0.14 (71)3.02±0.14 (81)**
RV L4.63±0.21 (216)4.20±0.23 (196)**
DL,CO/VA  mL·min−1·mmHg−1·L−13.06±0.17 (81)3.01±0.18 (80)
MIP cmH2O47±4 (58)56±5 (70)**
Pre-exercise breathing pattern
 IC L1.82±0.13 (65)2.15±0.11 (78)**
 IRV L1.19±0.121.49±0.11**
VT L0.63±0.030.66±0.03
fR breaths·min−119.8±0.719.7±0.8
VT/tI L·s−10.59±0.030.59±0.03
VT/tE L·s−10.32±0.010.34±0.02*
tE s2.04±0.092.02±0.11
  • Data are presented as mean±sem (per cent predicted)

  • FEV1: forced expiratory volume in one second

  • FVC: forced vital capacity

  • PEFR: peak expiratory flow rate

  • FEF50%: forced expiratory flow when 50% of the FVC has been exhaled

  • FIF50%: forced inspiratory flow when 50% of the FVC has been exhaled

  • TLC: total lung capacity

  • FRC: functional residual capacity

  • SVC: slow expiratory vital capacity

  • RV: residual volume

  • DL,CO: single-breath diffusing capacity of the lung for carbon monoxide

  • VA: alveolar volume

  • MIP: maximal inspiratory mouth occlusion pressure

  • IC: inspiratory capacity

  • IRV: inspiratory reserve volume

  • VT: tidal volume

  • fR: respiratory frequency

  • tI: inspiratory time

  • VT/tI: mean inspiratory tidal flow rate

  • tE: expiratory time

  • VT/tE: mean expiratory tidal flow rate

  • #: reported immediately prior to exercise andafter breathing on a mouthpiece at rest for ≥3 min (steady state)

  • *, **: p<0.05, p<0.01 versus placebo

  • (1 mmHg=0.133 kPa.)